GeneDx is trading 4.04% down at $79.06, reversing after closing at $82.39 on August 12, 2026, with no credible August 13 company-specific announcement identified to explain the decline.
- Latest identifiable company news was an August 11 online exome-testing offering.
- August 3 earnings showed $114.4 million revenue and reaffirmed 2026 guidance.
- Broader markets are higher, so macro sentiment does not clearly explain GeneDx’s opposite-direction move; volume and activity remain moderate during the open session.